Taxotere Promotional Efforts Will Focus On Metastatic Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Taxotere promotional efforts regarding metastatic breast cancer use will be a "major field of activity during the months to come in the U.S.," Sanofi-Aventis Exec VP-Pharmaceutical Operations Hanspeter Spek said
You may also be interested in...
Sanofi-Aventis’ Taxotere Gains New Indication For Head And Neck Cancer
Approval is based on data showing progression-free survival of 11.4 months.
Sanofi-Aventis’ Taxotere Gains New Indication For Head And Neck Cancer
Approval is based on data showing progression-free survival of 11.4 months.
Taxotere Could Get Boost From NICE Prostate Cancer Nod
U.K.’s National Institute for Health & Clinical Excellence recommends coverage of Sanofi-Aventis’ docetaxal for hormone-refractory metastatic prostate cancer.